Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Other Working Capital Changes (2016 - 2025)

Historic Other Working Capital Changes for Tg Therapeutics (TGTX) over the last 10 years, with Q3 2025 value amounting to $30.6 million.

  • Tg Therapeutics' Other Working Capital Changes rose 1971.7% to $30.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $35.0 million, marking a year-over-year increase of 9004.51%. This contributed to the annual value of -$2.3 million for FY2020, which is 6307.8% down from last year.
  • Tg Therapeutics' Other Working Capital Changes amounted to $30.6 million in Q3 2025, which was up 1971.7% from $5.3 million recorded in Q2 2025.
  • Tg Therapeutics' 5-year Other Working Capital Changes high stood at $30.6 million for Q3 2025, and its period low was -$6.8 million during Q1 2022.
  • Moreover, its 5-year median value for Other Working Capital Changes was $1.0 million (2023), whereas its average is $3.4 million.
  • As far as peak fluctuations go, Tg Therapeutics' Other Working Capital Changes crashed by 127286.14% in 2023, and later soared by 233918.02% in 2024.
  • Over the past 5 years, Tg Therapeutics' Other Working Capital Changes (Quarter) stood at $1.3 million in 2021, then crashed by 127.06% to -$339000.0 in 2022, then tumbled by 1272.86% to -$4.7 million in 2023, then decreased by 19.55% to -$5.6 million in 2024, then skyrocketed by 650.54% to $30.6 million in 2025.
  • Its Other Working Capital Changes stands at $30.6 million for Q3 2025, versus $5.3 million for Q2 2025 and $4.6 million for Q1 2025.